STEM CELLS & EXOSOMES

# Do mesenchymal stem cells and exosomes repair cartilage or slow aging?

How paracrine signaling via TGF-beta, IL-10, and extracellular vesicles works in localized joint trials versus unproven systemic infusions.

LetsGo Editorial · LetsGo Editorial · 17 November 2026 · 12 min read

Commercial clinics market intravenous stem cells and exosomes as systemic tissue rebuilders, yet biopsy and tracking studies show infused cells rarely survive or engraft for more than a few days.

When mesenchymal stromal cells (MSCs) are injected into a joint or vein, the vast majority do not permanently integrate into host tissue or differentiate into new cartilage, muscle, or organ parenchyma. Instead, their biological activity comes from the transient release of soluble cytokines, growth factors, and membrane-bound extracellular vesicles known as exosomes. While localized intra-articular injections of MSCs and umbilical-cord MSC-derived exosomes have entered early human randomized controlled trials for conditions like knee osteoarthritis, systemic intravenous infusions for general aging lack controlled human outcome data and carry distinct biological trade-offs.

## What it is

In adult regenerative medicine, the term "stem cell therapy" almost always refers to mesenchymal stromal cells (MSCs). Unlike embryonic stem cells or induced pluripotent stem cells (iPSCs), which can differentiate into any cell type in the body and carry a high risk of forming teratomas (tumors), MSCs are multipotent progenitor cells harvested from adult bone marrow, adipose (fat) tissue, or perinatal tissues such as umbilical cord Wharton's jelly and placenta. In laboratory culture, MSCs express specific surface markers (CD73, CD90, CD105) and lack hematopoietic markers (CD14, CD34, CD45, HLA-DR). Because they express low levels of major histocompatibility complex class II (MHC-II) proteins, allogeneic (donor-derived) MSCs provoke a muted immediate immune response, though they are eventually cleared by the recipient's immune system. Exosomes are a subset of small extracellular vesicles (sEVs), measuring roughly 30 to 150 nanometers in diameter, that are secreted by MSCs and virtually all other mammalian cells. Formed inside the cell within multivesicular bodies and released when those bodies fuse with the plasma membrane, exosomes are lipid bilayer packets displaying tetraspanin surface proteins (CD9, CD63, CD81). Inside, they carry a cargo of messenger RNAs (mRNAs), microRNAs (miRNAs), lipids, and signaling proteins derived from the parent cell. In clinical practice, MSCs and exosomes are categorized as biological products. Autologous preparations use a patient's own bone marrow aspirate concentrate (BMAC) or stromal vascular fraction (SVF) from liposuction. Allogeneic preparations use expanded cells or purified exosome secretomes harvested from screened umbilical cord or placental tissue banks. Because cell-free exosomes cannot self-replicate, they avoid the theoretical risk of ectopic tissue formation or malignant transformation associated with live cells, and they can be filtered and stored at ultra-low temperatures without toxic cryoprotectants like dimethyl sulfoxide (DMSO).

## Why it is used

Clinicians and researchers use MSCs and their exosomes for two distinct reasons: localized tissue modulation in orthopedics or wound care, and experimental systemic immune modulation. The primary clinical application

with human trial data is intra-articular injection for mild-to-moderate knee osteoarthritis (Kellgren-Lawrence grades II and III). In an osteoarthritic joint, chondrocytes (cartilage cells) become senescent, and synovial macrophages polarize toward a pro-inflammatory M1 phenotype, secreting interleukin-1 beta (IL-1b), tumor necrosis factor-alpha (TNF-a), and matrix metalloproteinases (MMP-13) that degrade type II collagen and aggrecan. Standard treatments like corticosteroid injections reduce pain temporarily but accelerate cartilage volume loss over repeated cycles. Hyaluronic acid (viscosupplementation) offers mechanical lubrication with modest symptom relief. Biologics like MSCs and exosomes are introduced to shift the intra-articular environment from catabolic breakdown toward anabolic repair without the chondrotoxicity of steroids. Outside of orthopedics, MSCs are investigated in clinical trials for graft-versus-host disease (GvHD), fistulizing Crohn's disease, and ischemic heart failure. In the commercial longevity sector, intravenous infusions of umbilical-cord MSCs or exosomes are sold to asymptomatic adults under the premise that they replenish exhausted endogenous stem cell pools and reduce chronic low-grade systemic inflammation (inflammaging). However, localized joint symptom improvements in selected osteoarthritis cohorts do not generalize to systemic regeneration packages sold to healthy individuals.

## How it helps

For decades, the assumed mechanism of MSC therapy was cell replacement: injected cells would home to damaged cartilage or myocardium, engraft, and differentiate into new chondrocytes or cardiomyocytes. Biodistribution studies in animals and humans refuted this model. When MSCs are infused intravenously, roughly 80% to 90% are physically trapped in the pulmonary capillary bed within minutes due to their cell size (15 to 30 micrometers), a phenomenon known as the pulmonary first-pass effect. Most trapped cells undergo apoptosis (programmed cell death) or phagocytosis by host macrophages within 24 to 72 hours. Even when injected directly into a joint space, few cells survive past a few weeks. The actual mechanism shown across preclinical models and human synovial fluid analyses is paracrine signaling and efferocytosis. While alive, MSCs sense inflammatory cytokines (like interferon-gamma and TNF-a) and respond by secreting anti-inflammatory and trophic molecules: - Transforming growth factor-beta (TGF-b) and insulin-like growth factor-1 (IGF-1), which stimulate endogenous chondrocytes to synthesize proteoglycans and type II collagen. - Interleukin-10 (IL-10), prostaglandin E2 (PGE2), and indoleamine 2,3-dioxygenase (IDO), which suppress T-cell proliferation and shift synovial macrophages from the pro-inflammatory M1 state to the reparative, anti-inflammatory M2 state. - Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2), which directly block MMP-13 and ADAMTS-5 from cleaving cartilage matrix. Furthermore, when infused MSCs die in the lungs or joint space, host macrophages engulf the apoptotic cellular debris (efferocytosis). This engulfment reprograms the host macrophages to downregulate NF-kB inflammatory pathways and release systemic IL-10 and TGF-b. In short, the host's immune response to dying MSCs drives much of the anti-inflammatory effect. MSC-derived exosomes isolate the vesicular component of this paracrine mechanism. Because exosomes are 100 times smaller than whole cells, they easily penetrate dense extracellular cartilage matrices and cross physiological barriers. Once internalized by target chondrocytes or macrophages via endocytosis, exosomes release microRNAs that regulate gene expression post-transcriptionally. In cartilage and animal models, exosomal miR-140-5p and miR-92a-3p inhibit Wnt/beta-catenin signaling and ADAMTS-5 expression, preserving cartilage matrix, while miR-21 and miR-146a dampen Toll-like receptor (TLR4) and NF-kB inflammatory cascades. In human clinical evidence, this mechanism translates primarily to symptom modification rather than structural regrowth. Meta-analyses of randomized controlled trials evaluating intra-articular MSCs (typically involving 15 to 100 patients per trial followed for 6 to 12 months) demonstrate statistically significant reductions in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scores and Visual Analog Scale (VAS) pain scores compared to saline or hyaluronic acid. A reliable single effect size across all MSC preparations does not exist because cell sources (adipose vs. bone marrow vs. umbilical), passage numbers, and viability vary widely across studies. For isolated exosomes, human clinical evidence is at an early stage. A 2025 paper in the Journal

of Translational Medicine reported preclinical cartilage regeneration work alongside an early randomized, double-blind, ascending-dose human clinical trial of umbilical-cord MSC-derived exosomes injected intra-articularly in patients with knee osteoarthritis. The investigators framed safety and tolerability as the primary endpoint, observing no severe treatment-related adverse events across the dose cohorts, while improvements in clinical knee symptom scores (such as WOMAC and VAS) and MRI cartilage assessments were recorded as secondary observations. A critical non-obvious synthesis for patients and physicians is the disconnect between symptom relief and structural tissue regeneration. In both MSC and exosome trials for osteoarthritis, patients frequently report substantial drops in joint pain within 4 to 12 weeks—long before hyaline cartilage could biologically regenerate. Even at 12-month follow-ups, standard structural MRI metrics (such as joint space width or total cartilage volume) often remain unchanged, even when advanced compositional MRI (T2 mapping, which measures water content and collagen fiber orientation) shows stabilization. The clinical benefit is driven primarily by quieter synovial inflammation and reduced nociceptor (pain receptor) sensitization in the joint capsule and subchondral bone, not the regrowth of a new cartilage pad.

## Who should try it

In an evidence-based clinical setting, candidates for localized MSC or exosome therapy are adults with symptomatic, mild-to-moderate osteoarthritis (Kellgren-Lawrence grades II to III) who have not responded adequately to mechanical load management, targeted strength training, weight optimization, or first-line intra-articular therapies (such as platelet-rich plasma or hyaluronic acid), and who wish to delay or avoid total joint arthroplasty. Patients with grade IV "bone-on-bone" osteoarthritis generally respond poorly to biologics because the resident chondrocyte population and extracellular scaffold required to respond to paracrine signals are already lost. Trade-offs, risks, and contraindications require careful weighting: - Regulatory status and quality control: Outside of specific approved indications (such as hematopoetic stem cell transplantation for hematologic malignancies or specific approved cell therapies for pediatric graft-versus-host disease and Crohn's fistulas), MSC and exosome products are largely unapproved by strict regulatory bodies like the FDA and EMA. Commercial exosome vials sold outside of registered clinical trials frequently suffer from batch-to-batch inconsistency; independent laboratory analyses of commercial vials have found products containing minimal intact vesicles, high levels of bovine serum albumin contaminants from culture media, or degraded RNA. - Infection and immune reactions: Unregulated umbilical cord blood and exosome products have caused documented outbreaks of severe bacterial infections (including Escherichia coli and Enterobacter cloacae septicemia and septic arthritis) due to sterile processing failures. Allogeneic products also carry a risk of viral transmission if donor screening is incomplete, and repeated allogeneic cell infusions can induce anti-HLA antibodies (alloimmunization). - Oncological and vascular risks: Because MSCs and their exosomes secrete pro-angiogenic factors like vascular endothelial growth factor (VEGF) and can suppress local anti-tumor immunity, active malignancy or a recent history of cancer is a strict contraindication. Intravenous infusions of high-dose MSCs carry a small but documented risk of pulmonary embolism or microvascular thrombosis because MSCs express tissue factor (CD142), which triggers the coagulation cascade upon contact with blood. - Cost and opportunity cost: Out-of-pocket costs typically range from $3,000 to $8,000 for a single localized joint injection and $10,000 to $25,000 or more for systemic intravenous guides at international clinics. For an asymptomatic 50-year-old seeking healthspan extension, spending five figures on an unproven intravenous exosome drip carries a substantial opportunity cost compared to investing in comprehensive lipid and metabolic optimization, VO2max and resistance training coaching, and high-resolution diagnostic imaging.

## Measurements that show improvement

Because subjective placebo responses are exceptionally strong in orthopedic injection trials and longevity interventions, anyone undergoing a localized or systemic guide (ideally within a registered clinical trial) should

track objective functional, structural, and biochemical markers. For localized joint interventions (such as knee osteoarthritis): - Validated patient-reported outcome measures: Track the WOMAC score (measuring pain, stiffness, and physical function) or the Knee Injury and Osteoarthritis Outcome Score (KOOS) at starting point, 1 month, 3 months, 6 months, and 12 months. A clinically meaningful improvement is typically a reduction of at least 15% to 20% from starting point WOMAC pain scores. - Structural and compositional imaging: Standard weight-bearing X-rays are too insensitive to detect early changes. Use 3-Tesla MRI with T2 mapping or dGEMRIC (delayed gadolinium-enhanced MRI of cartilage) at starting point and 12 months. A favorable response is a decrease or stabilization in cartilage T2 relaxation times (indicating lower water content, less inflammation, and more organized collagen fibrils) and a reduction in subchondral bone marrow lesions (BMLs) and synovitis volume. - Functional biomechanics: Track pain-free single-leg isometric quadriceps strength (via dynamometry) and daily step count or load tolerance without post-activity joint effusion. For systemic inflammation and biological age tracking: - High-sensitivity C-reactive protein (hs-CRP) and GlycA: If an intervention genuinely lowers systemic chronic inflammation, hs-CRP should decrease (ideally remaining below 1.0 mg/L) and GlycA (an NMR-measured composite marker of systemic acute-phase glycoproteins) should trend downward over 4 to 12 weeks. Note that an acute spike in hs-CRP within 24 to 72 hours post-infusion is common and reflects the innate immune clearance of the infused material rather than chronic worsening. - Cytokine panels: Research settings track serum IL-6, TNF-a, and IL-10, though diurnal variation makes single commercial blood draws noisy. - Epigenetic and physiological BioAge: While commercial clinics claim exosomes reverse epigenetic clocks (such as GrimAge or DunedinPACE), no randomized controlled human trial has validated that MSC or exosome infusions reliably reduce epigenetic age or improve hard physiological aging markers like VO2max, heart rate variability (HRV), arterial stiffness (pulse wave velocity), or grip strength. Tracking a composite BioAge panel before and 3 to 6 months after an intervention allows a patient and their physician to verify whether expensive therapies actually move starting point physiology beyond what structured exercise and metabolic programs achieve.

## Products and services

These LetsGo products and services sit next to this subject. They are not a prescription. A link is not evidence that the product causes the change discussed above. - [LetsGo Academy](/academy) — The teaching track for coaches who use these explainers with members. - [LetsGo programmes](/programs) — Coached programmes. Not a clinic menu and not a promise of a result.

## Practical takeaways

- Before considering any biologic injection for joint pain, confirm your osteoarthritis grade with a weight-bearing X-ray or 3T MRI; mild-to-moderate cases (grades II-III) have clinical trial support for symptom relief, whereas grade IV bone-on-bone disease rarely responds.
- Exhaust high-yield, low-risk interventions first: progressive quadriceps and hip abductor strength training, weight optimization, and clinically validated intra-articular options like leukocyte-poor platelet-rich plasma (PRP).
- If pursuing MSC or exosome therapy for osteoarthritis, prioritize registered clinical trials (searchable on ClinicalTrials.gov) that use standardized GMP-grade manufacturing, sterility testing, and verified vesicle counts.
- Avoid commercial intravenous stem cell or exosome infusions marketed for general anti-aging or wellness tourism, as they lack human RCT efficacy data and carry documented risks of contamination and pro-coagulant pulmonary trapping.
- Use objective biomarkers—such as WOMAC pain scores and 3T MRI T2 mapping for joints, or hs-CRP and GlycA for systemic inflammation—at starting point and 3 to 6 months post-procedure to separate true

physiological change from placebo.

## Safety note

Unregulated stem cell and exosome infusions carry documented risks of severe bacterial infection, viral transmission, allergic reactions, microvascular clotting, and potential stimulation of undiagnosed malignancies. Never receive intravenous or intra-articular biologics outside of a regulated clinical environment with verified sterility, donor screening, and physician oversight.

## Disclaimer

This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified physician before making decisions about regenerative medicine, orthopedic procedures, or longevity interventions.

Mesenchymal stromal cells and their exosomes represent a legitimate frontier in localized immunomodulation, acting as biological signalers that quiet synovial inflammation and protect surviving cartilage matrix rather than rebuilding organs from scratch. Early human trials—including ascending-dose randomized studies of umbilical-cord MSC exosomes in knee osteoarthritis—support their safety and potential to reduce joint pain and improve function in carefully selected patients. However, translating localized joint symptom relief into claims of systemic aging reversal is scientifically unfounded. Until large-scale human trials establish long-term safety, standardized manufacturing, and hard clinical outcomes, high-agency adults are best served by restricting these biologics to regulated orthopedic trials while relying on proven metabolic, cardiovascular, and mechanical interventions to drive systemic healthspan.